Equity
Amgen·Balance Sheet Statement·11 metrics
Breakdown
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Total liabilities and stockholders' equity | $90.9B | $90.9B | $91.8B | $89.4B | $87.9B | $90.1B | $90.6B | $92.5B |
| Common stock | $33.2B | $33.4B | $33.5B | $33.6B | $33.7B | $33.8B | $34.0B | $34.0B |
| Retained earnings | -$27.1B | -$25.5B | -$27.6B | -$27.1B | -$25.7B | -$23.8B | -$25.1B | -$24.7B |
| Total stockholders' equity | $5.9B | $7.5B | $5.9B | $6.2B | $7.4B | $9.6B | $8.7B | $9.2B |
| Share Repurchase Authorization Limit | $7.0B | $7.0B | — | $6.8B | $6.8B | $6.8B | — | $6.8B |
| Share Repurchase Program - Amount Remaining | $7.0B | $7.0B | — | $6.8B | $6.8B | $6.8B | — | $6.8B |
| Common stock | 2.8B | 2.8B | 33.5B | 2.8B | 2.8B | 2.8B | 2.8B | 2.8B |
| Accumulated other comprehensive income (loss) | -$155.0M | -$336.0M | -$66.0M | -$231.0M | -$544.0M | -$422.0M | -$258.0M | -$190.0M |
| Common Stock Par Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Unrealized Gains on Investments | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| Unrealized Losses on Investments (Before Tax) | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |